Grounded valuation uses a normalized EV/EBITDA multiple of ~27x (in line with life sciences tools peers for low-double-digit margin, moderate growth, and strong balance sheet), applied to FY26 adjusted EBITDA midpoint ($60.5M), with $529M net cash added. Share count based on most recent reported (6…
Azenta (AZTA) Q3 2026: 9% Organic Growth Driven by Biorepository and CNI Momentum
Azenta’s third quarter delivered a clear step forward, with 9% organic growth anchored by recurring revenue strength in biorepositories and CNI. Multiomics showed early signs of stabilization, though North America remains mixed, and margin headwinds persist in capital equipment. As management leans into operational transformation and cost discipline, investors should watch execution on modularization, commercial leadership, and the durability of recurring revenue as key levers for sustained improvement.
Summary
- Recurring Revenue Strength: Biorepositories and CNI drove growth and stability, outpacing legacy capital equipment.
- Multiomics Turnaround Underway: Execution improvements and new leadership signal early stabilization, but U.S. demand still lags.
- Margin Expansion Hinges on Cost Actions: Operational transformation and modular product moves are critical to restoring profitability.
Business Overview
Azenta provides sample management and multiomics solutions to life sciences, pharmaceutical, and biotechnology customers. The company generates revenue through two main segments: Sample Management Solutions (SMS, including biorepositories, consumables, and automated storage systems) and Multiomics (services and products for gene synthesis, sequencing, and clinical workflows). Over half of Azenta’s revenue now comes from recurring sources, such as storage services and consumables, providing a more stable revenue base compared to capital equipment sales.
Performance Analysis
Azenta delivered $161 million in revenue, up 12% as reported and 9% organically, exceeding expectations with broad-based growth across both segments. Biorepositories and CNI, the company’s recurring revenue engines, continued to outperform, demonstrating resilience and sequential improvement. Multiomics revenue grew 8% organically, supported by strong execution in Europe and China and a modest rebound in North America, though U.S. research spending remains below prior-year levels.
Gross margin pressures persisted, falling 140 basis points year over year to 46.2%, primarily due to under-absorption in automated stores, ongoing Sanger sequencing headwinds, and remediation costs. While adjusted EBITDA improved sequentially, investments in commercial capabilities and product development, alongside near-term dilution from the UK BioCenter (UKBC) acquisition, limited bottom-line leverage. Free cash flow was negative, reflecting working capital usage and lower deferred revenue, but the balance sheet remains debt-free with $529 million in cash and equivalents.
- Recurring Revenue Outpaces Capital Equipment: Biorepositories and CNI, over 50% of total revenue, posted robust growth, offsetting softness in automated stores.
- Multiomics Regional Divergence: Europe and China delivered double-digit growth, while North America showed only modest sequential gains.
- Margin Headwinds from Stores and Sanger: Quality remediation and lower volumes in capital equipment diluted overall profitability.
Operational improvements in multiomics and recurring businesses are creating a more stable foundation, but legacy capital equipment and Sanger sequencing remain structural drags.
Executive Commentary
"While these results reflect improved execution, our broader turnaround remains underway and sustained performance will require consistent execution over multiple quarters. The operational transformation we began last year in sample management solutions is further along and has helped us strengthen our foundation. Multiomics remains a central focus of our broader transformation strategy."
John Marotta, President and Chief Executive Officer
"Adjusted EBITDA margins was approximately 11.4%, down slightly from prior year by 60 basis points, but up sequentially 610 basis points. Improved multi-omics revenue performance, continued growth in our reoccurring revenue businesses, biorepositories, and CNI, and the benefits of cost and restructuring actions implemented during the year supported higher profit during the quarter."
Lawrence Lin, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Recurring Revenue Model Drives Resilience
More than half of Azenta’s revenue is now recurring, with biorepositories and CNI delivering consistent growth and providing a buffer against capital equipment cyclicality. This shift enhances cash flow predictability and operational stability, especially as macro and funding volatility persist in the sector.
2. Multiomics Transformation and Regional Execution
Multiomics is a central pillar of Azenta’s long-term strategy. The company is executing targeted commercial and operational initiatives, including new leadership in North America and footprint rationalization, to improve scalability and profitability. While Europe and China are driving growth, North America remains a turnaround work-in-progress due to lingering research funding constraints and legacy Sanger drag.
3. Modularization and Product Simplification in Automated Stores
Transitioning automated stores to a modular, standardized approach is a key operational lever. This move is intended to reduce engineering complexity, lower execution risk, and improve quality, addressing a historically unpredictable and margin-dilutive product line. Early backlog build and customer interest are positive, but revenue contribution will likely be limited in the near term as project timing remains variable.
4. Disciplined Capital Allocation and Portfolio Simplification
Azenta completed the divestiture of B Medical Systems and continues to pursue strategic M&A and share repurchases. The company’s strong balance sheet enables flexibility in capital deployment, with a focus on high-return opportunities, portfolio simplification, and disciplined M&A—though management remains cautious given valuation disconnects in the market.
5. Margin Expansion Dependent on Cost Actions
Margin improvement will require sustained execution on cost optimization in stores, Sanger, and organizational structure. Management outlined ongoing restructuring, productivity initiatives, and operational discipline as critical to achieving long-term EBITDA margin targets of 18% to 20%.
Key Considerations
Azenta’s quarter signals early progress on operational transformation, but the path to sustained improvement will be defined by execution in several high-impact areas:
Key Considerations:
- Recurring Revenue Foundation: Biorepositories and CNI now anchor the business, providing resilience and visibility, but require continued investment to sustain growth.
- Multiomics Inflection Point: Early signs of stabilization, especially in Europe and China, must be translated into durable gains in North America for the turnaround to take hold.
- Modularization as a Risk Mitigator: Standardizing automated stores is essential to reduce margin volatility and restore confidence in capital equipment execution.
- Margin Recovery Contingent on Cost Actions: Operational discipline and restructuring are needed to offset persistent headwinds from legacy businesses and new investments.
- Capital Allocation Flexibility: Strong cash position allows for opportunistic buybacks and targeted M&A, but management’s discipline will be tested as market conditions shift.
Risks
Azenta faces persistent risks from uneven research funding, especially in North America, and ongoing Sanger sequencing decline. Capital equipment sales remain lumpy, with project timing and conversion still unpredictable. Margin recovery depends on successful execution of cost actions and modularization, while macro and FX headwinds could further pressure results. Management’s cautious tone underscores the need for sustained, multi-quarter execution to deliver on long-term targets.
Forward Outlook
For Q4 2026, Azenta guided to:
- Adjusted EBITDA of $20 to $23 million
- Continued low single-digit revenue growth, with SMS expected to grow and multiomics flat to slightly down
For full-year 2026, management raised guidance to:
- Total reported revenue of $613 to $618 million
- Organic revenue roughly flat to up 1% year over year
- Adjusted EBITDA of $59 million to $62 million
Management highlighted:
- Disciplined outlook for Q4, citing tough comps in multiomics and ongoing demand uncertainty
- Focus on cost optimization, especially in stores and Sanger, and continued investment in commercial capabilities
Takeaways
Azenta’s Q3 marks a genuine step forward in operational execution and recurring revenue growth, but the turnaround story is still in its early innings.
- Recurring Revenue Anchors Stability: Biorepositories and CNI offsetting legacy headwinds, but require ongoing commercial investment to maintain momentum.
- Execution Remains the Deciding Factor: Modularization, cost actions, and North American multiomics recovery are critical to margin expansion and long-term value creation.
- Investors Should Watch for Multi-Quarter Consistency: The next few quarters will reveal whether early gains can be sustained and broadened across geographies and segments.
Conclusion
Azenta’s Q3 performance exceeded expectations, driven by recurring revenue strength and operational improvements. However, the company’s transformation remains a work in progress, with future success dependent on disciplined execution in cost control, modularization, and commercial leadership. Investors should monitor the durability of recurring revenue and progress on margin recovery as key signals for the next phase of growth.
Industry Read-Through
Azenta’s results reinforce the sector-wide shift toward recurring revenue and operational discipline in life sciences tools and services. The ongoing challenges in capital equipment sales and U.S. research funding echo trends seen across the industry, with European and Chinese markets providing relative strength. Modularization and product standardization are emerging as best practices for margin stability, while disciplined capital allocation and portfolio simplification are increasingly necessary to weather macro and funding volatility. Competitors and peers should note the importance of recurring revenue models and proactive cost management in sustaining growth through industry cycles.